A currently recruiting Phase 2 clinical trial from Sanofi, “Efficacy and Safety…
Articles by Maureen Newman
The American Thoracic Society (ATS) now recommends that some patients with idiopathic pulmonary fibrosis (IPF)…
Pharmaxis Ltd. and Synairgen plc are entering into a research collaboration to develop a therapeutic for idiopathic pulmonary fibrosis (IPF).
An accumulation of data from multiple different studies supports the use of pirfenidone (Esbriet, from Roche) to treat idiopathic pulmonary…
A protein expressed solely by cells lining the airways is at the center of an interesting new strategy that may…
Dr. Claudia A. Staab-Weijnitz and Dr. Oliver Eickelberg at the Comprehensive Pneumology Center in the University of Munich are studying…
ProMetic Life Sciences Inc. recently validated the potential for its experimental drug target PBI-4050 to treat patients with idiopathic pulmonary…
Building a new set of lungs for patients with pulmonary fibrosis is becoming closer to reality as a result of cutting-edge…
Hard at work in the laboratory of Dr. Christine Kim Garcia, Associate Professor of Internal Medicine at UT Southwestern Medical…
Boehringer Ingelheim, a leader in developing treatments for lung diseases, sponsored a phase 2 clinical trial investigating four doses of…